Don Davies on Questions Passed as Orders for Returns

With respect to any analysis by officials from Industry Canada and Health Canada on the impact of Patent Term Restoration (PTR) in Canada: (a) what options for implementing a PTR system in Canada have been evaluated by officials at Industry Canada and Health Canada; (b) what are the estimated impacts on the cost of drugs in Canada that would arise from the implementation of a PTR system based on that which exists in the European Union; (c) what are the estimated impacts on the cost of drugs in Canada that would arise from other options to implement a PTR system in Canada, as analysed by officials; (d) what was the detailed methodology employed to estimate the impacts on the cost of drugs in Canada of these various options; (e) which of these options is being proposed by the government in the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations; (f) what is the final title of any report(s) or studies prepared by, or on behalf of, these departments concerning CETA within the last two years; (g) will the government be releasing any of these reports publicly; and (h) what were the findings of these reports regarding costs to Canadian governments or the Canadian economy of patents?